Lion Biotechnologies Enters Clinical and Preclinical Research Collaboration With MedImmune
December 21 2015 - 8:00AM
Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company
that is developing novel cancer immunotherapies based on
tumor-infiltrating lymphocytes (TIL), today announced that it has
entered into a collaboration to conduct clinical and preclinical
research in immuno-oncology with MedImmune, the global biologics
research and development arm of AstraZeneca.
Under the terms of the agreement, Lion will fund and conduct two
Phase 2a clinical trials combining MedImmune’s investigational
PD-L1 inhibitor durvalumab with TIL for the treatment of patients
with metastatic melanoma, and head and neck cancer. MedImmune will
supply durvalumab for the clinical trials. The purpose of the
studies is to establish a dosing regimen for this combination
therapy and assess its safety and efficacy.
Preclinical research under the agreement will focus on
identifying and evaluating therapeutically effective combinations
of MedImmune’s checkpoint antibodies, using TIL as an in vitro
model of the tumor microenvironment. The research will be funded by
MedImmune and conducted by Lion.
“This collaboration with MedImmune will allow us to investigate
combination strategies using TIL and immunotherapeutic agents,”
said Elma Hawkins, PhD, Lion’s president and chief executive
officer. “In preclinical studies, TIL and anti-PD-1/PD-L1
combination regimens have demonstrated significant anti-tumor
activity, suggesting a synergistic effect. We look forward to
working with MedImmune to further develop this approach and other
combination therapies that we believe have the potential to
meaningfully improve outcomes for patients.”
Dr. Ed Bradley, Senior Vice President, Oncology, MedImmune
, commented, “Our partnership with Lion underscores our
commitment to advancing immuno-oncology, as well as our belief that
combination therapies have the potential to be one of the most
effective ways of treating cancer. We look forward to leveraging
Lion’s expertise in the discovery and development of TIL, both in
the preclinical setting and in our planned combination trials in
melanoma and head and neck cancer.”
About Lion Biotechnologies
Lion Biotechnologies, Inc. is a clinical-stage biotechnology
company focused on the development of cancer immunotherapy products
for the treatment of various cancers. The company’s lead
product candidate is an adoptive cell therapy using
tumor-infiltrating lymphocytes (TIL) for the treatment of patients
with refractory metastatic melanoma, and is based on a
clinical Cooperative Research and Development Agreement with the
National Cancer Institute. TIL therapy is also being evaluated in
physician-sponsored clinical trials at MD Anderson Cancer Center
and Moffitt Cancer Center. For more information, please
visit http://www.lionbio.com.
Forward Looking Statements
This press release contains certain forward-looking statements
that are subject to a number of risks and uncertainties described
in the Company’s most recently filed quarterly report on Form 10-Q
and annual report on Form 10-K. Except as permitted by law, the
Company undertakes no obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Investor Relations
The Trout Group
Elizabeth Broder
646-378-2945
ebroder@troutgroup.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Apr 2023 to Apr 2024